{"id":"W2042060010","doi":"10.1089/apc.2012.0135","title":"A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy","year":2012,"lang":"en","type":"article","venue":"AIDS Patient Care and STDs","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute of Allergy and Infectious Diseases; Pfizer; National Institute of Mental Health; EMD Serono; National Institutes of Health; International AIDS Society; GlaxoSmithKline; ViiV Healthcare; Gilead Sciences; Ontario HIV Treatment Network; National Institute on Aging; Bristol-Myers Squibb","keywords":"Raltegravir; Medicine; Nucleoside Reverse Transcriptase Inhibitor; Reverse-transcriptase inhibitor; Protease inhibitor (pharmacology); Virology; Integrase inhibitor; Reverse transcriptase; Human immunodeficiency virus (HIV); Randomized controlled trial; Pharmacology; Internal medicine; Antiretroviral therapy; Viral load; Polymerase chain reaction; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001521486,0.001752464,0.004028431,0.0005287147,0.0005005071,0.001312856,0.001182171,0.002808374,0.01164761],"category_scores_gemma":[0.002730036,0.0007857273,0.001472574,0.0003704464,0.001430744,0.001294501,0.000675083,0.003436807,0.00169494],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006693042,"about_ca_system_score_gemma":0.001302585,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00121521,"about_ca_topic_score_gemma":0.002519086,"domain_scores_codex":[0.9990497,0.0005352836,0.00006296607,0.0001597704,0.00004928444,0.0001429482],"domain_scores_gemma":[0.9987809,0.0004480412,0.0001829123,0.00009721313,0.00006965442,0.0004213614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9925649,0.002371777,0.0001327054,0.0001885911,0.0002340921,0.00002468131,0.00002211938,0.00008206128,0.0005505612,0.00006974906,0.0002196798,0.003539141],"study_design_scores_gemma":[0.969197,0.02958966,0.0003985504,0.00001526693,0.0001235923,0.00001344332,0.000017266,0.0001748942,0.00008471385,0.0001080626,0.0002711639,0.000006403126],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743807,0.005089784,0.0006237343,0.001622703,0.002197643,0.01007289,0.001348537,0.0002507211,0.004413191],"genre_scores_gemma":[0.9766638,0.002234115,0.001672568,0.00210037,0.0007099821,0.009762214,0.00106406,0.0000346764,0.005758242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01164761,"threshold_uncertainty_score":0.03896517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01113792086951531,"score_gpt":0.2463106696918898,"score_spread":0.2351727488223745,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}